A5081916808- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Histone Deacetylase Inhibitors Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Palliative Care and End-of-Life Issues
- Acute Lymphoblastic Leukemia research
- HIV/AIDS drug development and treatment
- Hematopoietic Stem Cell Transplantation
- Retinoids in leukemia and cellular processes
- Protein Degradation and Inhibitors
- Childhood Cancer Survivors' Quality of Life
- COVID-19 Clinical Research Studies
- COVID-19 and healthcare impacts
- Hematological disorders and diagnostics
- Multiple Myeloma Research and Treatments
- Cancer survivorship and care
- SARS-CoV-2 and COVID-19 Research
- Shoulder Injury and Treatment
- Lymphoma Diagnosis and Treatment
- Neutropenia and Cancer Infections
- CAR-T cell therapy research
- Orthopedic Surgery and Rehabilitation
- Nuclear Structure and Function
- Signaling Pathways in Disease
Massachusetts General Hospital
2016-2025
Harvard University
2014-2025
Keck Hospital of USC
2021-2022
California State University, Fresno
2018
University of California, San Francisco
2018
Palmetto Hematology Oncology
2016
The immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with cancer are poorly understood.We performed a prospective cohort study adults solid-organ or hematologic cancers to evaluate anti-SARS-CoV-2 immunoglobulin A/M/G spike antibodies, neutralization, ≥ 7 days following two doses mRNA-1273, BNT162b2, one dose Ad26.COV2.S. We analyzed responses by multivariate regression included data from 1,638 healthy controls, previously reported, for comparison.Between April July 2021,...
Abstract Purpose: Isocitrate dehydrogenase 1 (IDH1) mutations occur in 5% to 10% of patients with acute myeloid leukemia (AML). Ivosidenib is an IDH1 inhibitor, approved for use IDH1-mutated AML. Patients and Methods: We conducted a multicenter, phase I trial maintenance ivosidenib following allogeneic hematopoietic cell transplantation (HCT) was initiated between days 30 90 HCT continued up 12 28-day cycles. The first dose level 500 mg daily, reduction 250 if needed, 3 × de-escalation...
Isolated myeloid sarcoma (MS) is a rare extramedullary presentation of acute leukemia (AML). Little known about MS outcomes due to its rarity. A population-based analysis using the Survival, Epidemiology, and End Results (SEER) database was performed. We identified 345 patients, aged 15 or older, diagnosed with isolated between 1973 2010. Overall survival (OS) calculated compared non-MS AML log-rank test. Survival also evaluated based upon primary site disease presentation. The 3-year rate...
BACKGROUND Outcomes for patients with chronic myeloid leukemia (CML) have improved after the advent of tyrosine kinase inhibitors (TKIs), which target BCR/ABL fusion gene product. Nonetheless, differences in survival persist between age groups. The authors performed a retrospective cohort study using Surveillance, Epidemiology, and End Results (SEER) database to assess 5‐year overall (OS) various patient METHODS Patients who had diagnosis CML were identified SEER 19 registries database....
Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders associated with progression to leukemia and poor survival. Clonal hematopoiesis in people without an MDS diagnosis carries increased risk of cardiovascular death. Many clonally restricted mutations shared between patients those non-MDS hematopoiesis; therefore, we evaluated the death among MDS. We adults Surveillance, Epidemiology, End Results database National Cancer Institute compared them general population...
Abstract Purpose: Safety and preliminary clinical activity of FHD-286, a dual BRG1/BRM inhibitor, were evaluated in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome. Patients methods: In this multicenter, open-label, phase 1, dose escalation study (NCT04891757), received FHD-286 orally once daily (QD) at 2.5, 5, 7.5, 10 mg. Results: Forty (median age 65.5 years; 85% adverse genetic status; 65% ≥3 prior therapy lines) for 28 days (median). was not tolerated...
We sought to assess the safety of adding ixazomib, an oral proteasome inhibitor, a multi-agent treatment regimen for older adults with acute lymphoblastic leukemia (ALL). Patients 51 75 years age newly diagnosed ALL were screened. Induction consisted prednisone (P), vincristine (V), and doxorubicin (D). For BCR-ABL1+ patients, dasatinib was added. On Days 1, 8, 15 induction, ixazomib given orally. After induction patients received 1 cycle consolidation in which on 15. consolidation,...
We sought to identify features in routine evaluation of pre-hematopoietic cell transplantation (HCT) bone marrow samples from patients with acute myeloid leukemia (AML) that influenced patient outcome.Of 140 patients, evidence residual (RL) was identified 38 (27%) pre-HCT samples, as defined by 5% or more aspirate blasts, increased blood clustered necrotic blasts on biopsy specimens, and/or leukemia-associated karyotypic abnormalities.Morphologic RL significantly associated shorter...